Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04282746 | A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants | PHASE1 | COMPLETED | 17 | — | — | Feb 18, 2020 | Aug 17, 2020 | Apr 27, 2025 | 1 | Belgium |
Observed plasma concentrations of (S)-ketamine will be reported.
Observed plasma concentrations of nor-(S)-ketamine will be reported.
| Arm | Type | Description |
|---|---|---|
| JNJ-54135419 | EXPERIMENTAL | Participants will receive a single oral dose of JNJ-54135419-AAA oral solution for sublingual administration in 1 of 3 serial dose escalating cohorts in fasted conditions. |
| Name | Type | Description |
|---|---|---|
| JNJ-54135419 | DRUG | Single dose of JNJ-54135419 oral solution will be administered sublingually. |
Inclusion Criteria: * Body mass index (BMI) between 20.0 and 28.0 kilogram per meter square kg/m\^2 inclusive (BMI = weight/height\^2) with a minimum weight of 60 kilogram (kg) and a maximum of 100 kg * Participant must be healthy based on clinical laboratory tests performed at screening. If the re...